Group 1: New Stock Offerings - Medela's new stock offering has a subscription code of 920119, with an issue price of 41.88 yuan per share and a price-to-earnings ratio of 14.99 times, allowing a maximum subscription limit of 720,000 shares per account [2] Group 2: Fiscal Policy and Economic Measures - The Ministry of Finance will continue to implement a more proactive fiscal policy, aiming for increased total spending, improved structure, better efficiency, and stronger momentum, with necessary levels of fiscal deficit, total debt, and spending maintained through 2026 [3] - The Ministry of Finance has optimized the personal consumption loan interest subsidy policy, including credit card installment payments, removing restrictions on certain consumption areas, allowing all consumer loans to enjoy interest subsidies [3] - Starting April 1, 2026, export tax rebates for photovoltaic products will be canceled, and electronic product export tax rebates will be phased out over two years, promoting efficient resource use and guiding rational industrial structure adjustments [3] - Tax and fee preferential policies for community services such as elderly care, childcare, and housekeeping will continue, benefiting institutions providing these services [3] Group 3: Commodity Market Adjustments - The Shanghai Futures Exchange will adjust margin ratios and price fluctuation limits for futures contracts of copper, gold, and other commodities starting January 22, 2026 [4] - Domestic gasoline and diesel prices will increase by 85 yuan per ton due to rising international oil prices, marking the first price hike in 2026, with an average increase of 0.07 yuan per liter for 92 and 95 gasoline and 0 diesel [4] - Shanghai has released an action plan to enhance the linkage between spot and futures markets for non-ferrous metals, aiming to expand the international influence of "Shanghai prices" [4] Group 4: Company Earnings Forecasts - Huicheng Environmental Protection plans to increase its shareholding by 25 million to 50 million yuan [7] - JianTou Energy expects a net profit increase of approximately 253.38% year-on-year for 2025 [7] - Hikvision's performance report indicates a year-on-year growth of 18.46% in net profit attributable to shareholders for 2025 [7] - Longzi Co. anticipates a net profit increase of 245.25% to 302.8% year-on-year for 2025 [7] - Zhaoyan New Drug expects a net profit increase of 214% to 371% year-on-year for 2025 [8] - Huachen Equipment forecasts a net profit increase of 193.64% to 242.04% year-on-year for 2025 [8] - Qianyuan Power anticipates a net profit increase of 160% to 190% year-on-year for 2025 [8] - Jin Fang Energy expects a net profit increase of 123.97% to 193.7% year-on-year for 2025 [8] - Other companies such as Zhongfu Industrial, Batian Co., and Dongwei Technology also project significant year-on-year profit increases for 2025, ranging from 50% to over 300% [8][9]

（编辑 袁冠琳） 证券日报网讯 1月20日，恩威医药发布2025年度业绩预告称，公司预计2025年度归属于上市公司股东的 净利润为5，650万元～6，650万元，比上年同期3，749.75万元增长50.68%～77.35%。 ...

恩威医药(301331.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润5650万元至6650 万元，同比增长50.68%至77.35%;扣除非经常性损益后的净利润4900万元至5900万元，同比增长41.09% 至69.88%。 ...

新京报贝壳财经讯1月20日，恩威医药（301331）公告，预计2025年度净利润为5650万元至6650万元， 同比增长50.68%～77.35%。报告期内，预计非经常性损益对净利润的影响金额约为750万元。2025年业 绩上升的主要原因是主营业务收入增长带来净利润增加及股权激励计划成本摊销减少所致。 ...

恩威医药（301331）(301331.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润5650 万元至6650万元，同比增长50.68%至77.35%;扣除非经常性损益后的净利润4900万元至5900万元，同比 增长41.09%至69.88%。 ...

1、2025年业绩上升的主要原因是主营业务收入增长带来净利润增加及股权激励计划成本摊销减少所 致。2、报告期内，预计非经常性损益对净利润的影响金额约为750万元。 格隆汇1月20日丨恩威医药(301331.SZ)公布，预计2025年归属于上市公司股东的净利润5,650万元～ 6,650万元，比上年同期增长50.68%～77.35%，扣除非经常性损益后的净利润4,900万元～5,900万元，比 上年同期增长41.09%～69.88%。 ...

恩威医药公告，预计2025年度净利润为5650万元至6650万元，同比增长50.68%～77.35%。报告期内， 预计非经常性损益对净利润的影响金额约为750万元。2025年业绩上升的主要原因是主营业务收入增长 带来净利润增加及股权激励计划成本摊销减少所致。 ...

证券代码：301331 证券简称：恩威医药 公告编号：2026-001 恩威医药股份有限公司 2025 年度业绩预告 1、2025 年业绩上升的主要原因是主营业务收入增长带来净利润增加及股权激励计划成本摊销减少 所致。 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为正值且属于同向上升 50%以上情形 （1）以区间数进行业绩预告的 项 目 本报告期 上年同期 归属于上市公司股 东的净利润 5,650 ～ 6,650 比上年同期 3,749.75 增长 50.68% ～ 77.35% 扣除非经常性损益 后的净利润 4,900 ～ 5,900 比上年同期 3,472.96 增长 41.09% ～ 69.88% 二、与会计师事务所沟通情况 本次业绩预告相关数据是公司财务部门初步测算的结果，未经会计师事务所审计。公司已就本次业 绩预告有关事项与会计师事务所进行了预沟通，公司与会计师事务所在本期业绩预告方面不存在重大分 歧。 三、 ...

Market Overview - The Traditional Chinese Medicine (TCM) sector saw a slight increase of 0.31% on January 8, with WoHua Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4082.98, down 0.07%, while the Shenzhen Component Index closed at 13959.48, down 0.51% [1] Top Performers - WoHua Pharmaceutical (002107) closed at 7.13, up 5.63% with a trading volume of 298,400 shares and a turnover of 210 million yuan [1] - Enwei Pharmaceutical (301331) closed at 29.06, up 5.52% with a trading volume of 29,600 shares and a turnover of 85 million yuan [1] - Jinhua Co., Ltd. (600080) closed at 8.03, up 4.69% with a trading volume of 137,600 shares and a turnover of 110 million yuan [1] Underperformers - Jilin Aodong (000623) closed at 20.04, down 2.48% with a trading volume of 206,000 shares and a turnover of 416 million yuan [2] - Panlong Pharmaceutical (002864) closed at 34.32, down 1.58% with a trading volume of 149,000 shares and a turnover of 524 million yuan [2] - RY Pharmaceutical (600332) closed at 25.04, down 1.57% with a trading volume of 486,000 shares and a turnover of 122 million yuan [2] Capital Flow - The TCM sector experienced a net outflow of 493 million yuan from institutional investors, while retail investors saw a net inflow of 378 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2] Individual Stock Capital Flow - Huaren Sanjiu (6660000) had a net inflow of 57.91 million yuan from institutional investors, while it faced a net outflow of 51.38 million yuan from speculative funds [3] - Yunnan Baiyao (000538) saw a net inflow of 42.56 million yuan from institutional investors, but also experienced outflows from both speculative and retail investors [3] - Wanbangde (002082) had a net inflow of 26.36 million yuan from institutional investors, with outflows from speculative and retail investors [3]

Group 1 - Enwei Pharmaceutical's stock price increased by 5.16% on January 8, reaching 28.96 CNY per share, with a total market capitalization of 2.98 billion CNY [1] - The company has experienced a continuous rise in stock price for four consecutive days, with a cumulative increase of 5.8% during this period [1] - Enwei Pharmaceutical specializes in the research, production, and sales of traditional Chinese medicine and chemical drugs, focusing on gynecological products, pediatric medications, and respiratory system drugs [1] Group 2 - According to data, a fund managed by China Merchants Asset Management holds a significant position in Enwei Pharmaceutical, with 7,900 shares, accounting for 1.14% of the fund's net value [2] - The fund, China Merchants Asset Management Zhida Quantitative Stock Mixed Fund A, has generated a floating profit of approximately 11,200 CNY today and 11,900 CNY during the four-day rising period [2] - The fund has a total asset size of 20.91 million CNY and has achieved a year-to-date return of 3.7% [2]